MedTrace Logo

Medication Review in Chronic Complex or Polymedicated Patients After Hospital Discharge.

NCT05799430 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2023-09-15

No results posted yet for this study

Summary

The goal of this prospective multicentre clustered randomized controlled trial is to evaluate the effect on new hospitalization episodes of a multidisciplinary medication review in primary care patients with polypharmacy or chronic complex conditions after hospital discharge.

The multidisciplinary team will be integrated by a family physician (FP), a primary care nurse (PCN) and a primary care pharmacist (PCP). Patient will be adults aged 65 years and older. Polypharmacy refers to the use of 10 or more drugs based on information in electronic prescription software.

Research questions are:

In elderly patients with polypharmacy, which is the effect of an interdisciplinary medication review after hospital discharge in comparison with standard care, in terms of:

* new hospitalization episodes?
* number of drugs prescribed?
* prescribed drugs adequacy?

Conditions

  • Medication Review
  • Polypharmacy
  • Disease, Chronic

Interventions

BEHAVIORAL

Multidisciplinary medication review

FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps: 1. PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria. 2. PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations. 3. FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy. 4. FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented. 5. FP and PCN communicate to PCP final agreement with patient and/or carer 6. FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures

BEHAVIORAL

Control group

Usual care by FP an PCN

Sponsors & Collaborators

  • Andalusian Health Service

    collaborator OTHER_GOV

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • Teresa Molina, Pharm Dr · Andalusian Health Service. Spain

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-15
Primary Completion
2024-06-10
Completion
2024-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799430 on ClinicalTrials.gov